NCT00255346 - Dasatinib as Therapy for Myeloproliferative Disorders (MPDs) | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 15, 2005

Primary Completion Date

March 3, 2017

Study Completion Date

March 3, 2017

Conditions

Acute Myeloid LeukemiaMyelodysplastic SyndromesAgnogenic Myeloid MetaplasiaMyelofibrosisHypereosinophilic SyndromePolycythemia VeraMastocytosisLeukemia, Myelomonocytic, Chronic

Interventions

DRUG

Dasatinib (BMS-354825)

70 mg orally twice daily

Trial Locations (1)

77030

The University of Texas M.D. Anderson Cancer Center, Houston